{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:57:30Z","timestamp":1794329850606,"version":"4.9.0"},"reference-count":181,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Angiogenesis is the growth of new capillaries from the preexisting blood vessels. Glioblastoma (GBM) tumors are highly vascularized tumors, and glioma growth depends on the formation of new blood vessels. Angiogenesis is a complex process involving proliferation, migration, and differentiation of vascular endothelial cells (ECs) under the stimulation of specific signals. It is controlled by the balance between its promoting and inhibiting factors. Various angiogenic factors and genes have been identified that stimulate glioma angiogenesis. Therefore, attention has been directed to anti-angiogenesis therapy in which glioma proliferation is inhibited by inhibiting the formation of new tumor vessels using angiogenesis inhibitory factors and drugs. Here, in this review, we highlight and summarize the various molecular mediators that regulate GBM angiogenesis with focus on recent clinical research on the potential of exploiting angiogenic pathways as a strategy in the treatment of GBM patients.<\/jats:p>","DOI":"10.1007\/s12035-020-01892-8","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T07:02:33Z","timestamp":1583737353000},"page":"2461-2478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":411,"title":["Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma"],"prefix":"10.1007","volume":"57","author":[{"given":"Bhavesh K.","family":"Ahir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert H.","family":"Engelhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8786-5626","authenticated-orcid":false,"given":"Sajani S.","family":"Lakka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,9]]},"reference":[{"key":"1892_CR1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/978-1-60327-492-0_14","volume":"472","author":"H Ohgaki","year":"2009","unstructured":"Ohgaki H (2009) Epidemiology of brain tumors. Methods Mol Biol 472:323\u2013342. https:\/\/doi.org\/10.1007\/978-1-60327-492-0_14","journal-title":"Methods Mol Biol"},{"issue":"1","key":"1892_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00401-005-0991-y","volume":"109","author":"H Ohgaki","year":"2005","unstructured":"Ohgaki H, Kleihues P (2005) Epidemiology and etiology of gliomas. Acta Neuropathol 109(1):93\u2013108. https:\/\/doi.org\/10.1007\/s00401-005-0991-y","journal-title":"Acta Neuropathol"},{"issue":"suppl_5","key":"1892_CR3","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/nox158","volume":"19","author":"QT Ostrom","year":"2017","unstructured":"Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2017) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol 19(suppl_5):v1\u2013v88. https:\/\/doi.org\/10.1093\/neuonc\/nox158","journal-title":"Neuro Oncol"},{"issue":"3","key":"1892_CR4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s11060-011-0546-0","volume":"104","author":"SC Erridge","year":"2011","unstructured":"Erridge SC, Hart MG, Kerr GR, Smith C, McNamara S, Grant R, Gregor A, Whittle IR (2011) Trends in classification, referral and treatment and the effect on outcome of patients with glioma: a 20 year cohort. J Neuro-Oncol 104(3):789\u2013800. https:\/\/doi.org\/10.1007\/s11060-011-0546-0","journal-title":"J Neuro-Oncol"},{"issue":"6","key":"1892_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803\u2013820. https:\/\/doi.org\/10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"issue":"4","key":"1892_CR6","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-12-3002","volume":"19","author":"H Ohgaki","year":"2013","unstructured":"Ohgaki H, Kleihues P (2013) The definition of primary and secondary glioblastoma. Clin Cancer Res 19(4):764\u2013772. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3002","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1892_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","volume":"114","author":"DN Louis","year":"2007","unstructured":"Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97\u2013109. https:\/\/doi.org\/10.1007\/s00401-007-0243-4","journal-title":"Acta Neuropathol"},{"issue":"6","key":"1892_CR8","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s11864-006-0024-7","volume":"7","author":"K Palanichamy","year":"2006","unstructured":"Palanichamy K, Erkkinen M, Chakravarti A (2006) Predictive and prognostic markers in human glioblastomas. Curr Treat Options in Oncol 7(6):490\u2013504","journal-title":"Curr Treat Options in Oncol"},{"issue":"4","key":"1892_CR9","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/j.1750-3639.2009.00315.x","volume":"19","author":"OM Grauer","year":"2009","unstructured":"Grauer OM, Wesseling P, Adema GJ (2009) Immunotherapy of diffuse gliomas: biological background, current status and future developments. Brain Pathol 19(4):674\u2013693. https:\/\/doi.org\/10.1111\/j.1750-3639.2009.00315.x","journal-title":"Brain Pathol"},{"issue":"Suppl 5","key":"1892_CR10","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/nos218","volume":"14","author":"TA Dolecek","year":"2012","unstructured":"Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro-Oncology 14(Suppl 5):v1\u2013v49. https:\/\/doi.org\/10.1093\/neuonc\/nos218","journal-title":"Neuro-Oncology"},{"issue":"Pt 4","key":"1892_CR11","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/brain\/awq044","volume":"133","author":"S El Hallani","year":"2010","unstructured":"El Hallani S, Boisselier B, Peglion F, Rousseau A, Colin C, Idbaih A, Marie Y, Mokhtari K et al (2010) A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain 133(Pt 4):973\u2013982. https:\/\/doi.org\/10.1093\/brain\/awq044","journal-title":"Brain"},{"issue":"Pt 4","key":"1892_CR12","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1093\/brain\/awq063","volume":"133","author":"M Weller","year":"2010","unstructured":"Weller M (2010) Angiogenesis in glioblastoma: just another moving target? Brain 133(Pt 4):955\u2013956. https:\/\/doi.org\/10.1093\/brain\/awq063","journal-title":"Brain"},{"key":"1892_CR13","doi-asserted-by":"publisher","first-page":"351908","DOI":"10.1155\/2010\/351908","volume":"2010","author":"S Takano","year":"2010","unstructured":"Takano S, Yamashita T, Ohneda O (2010) Molecular therapeutic targets for glioma angiogenesis. J Oncol 2010:351908. https:\/\/doi.org\/10.1155\/2010\/351908","journal-title":"J Oncol"},{"issue":"7","key":"1892_CR14","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrc2868","volume":"10","author":"AS Chung","year":"2010","unstructured":"Chung AS, Lee J, Ferrara N (2010) Targeting the tumour vasculature: Insights from physiological angiogenesis. Nat Rev Cancer 10(7):505\u2013514. https:\/\/doi.org\/10.1038\/nrc2868","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"1892_CR15","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nm0603-653","volume":"9","author":"P Carmeliet","year":"2003","unstructured":"Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9(6):653\u2013660. https:\/\/doi.org\/10.1038\/nm0603-653","journal-title":"Nat Med"},{"issue":"7070","key":"1892_CR16","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/nature04478","volume":"438","author":"P Carmeliet","year":"2005","unstructured":"Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438(7070):932\u2013936. https:\/\/doi.org\/10.1038\/nature04478","journal-title":"Nature"},{"issue":"2","key":"1892_CR17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10555-007-9066-y","volume":"26","author":"D Liao","year":"2007","unstructured":"Liao D, Johnson RS (2007) Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 26(2):281\u2013290. https:\/\/doi.org\/10.1007\/s10555-007-9066-y","journal-title":"Cancer Metastasis Rev"},{"issue":"17","key":"1892_CR18","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1016\/j.febslet.2008.06.033","volume":"582","author":"JL Lin","year":"2008","unstructured":"Lin JL, Wang MJ, Lee D, Liang CC, Lin S (2008) Hypoxia-inducible factor-1alpha regulates matrix metalloproteinase-1 activity in human bone marrow-derived mesenchymal stem cells. FEBS Lett 582(17):2615\u20132619. https:\/\/doi.org\/10.1016\/j.febslet.2008.06.033","journal-title":"FEBS Lett"},{"issue":"6","key":"1892_CR19","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/sj.onc.1208305","volume":"24","author":"BL Petrella","year":"2005","unstructured":"Petrella BL, Lohi J, Brinckerhoff CE (2005) Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma. Oncogene 24(6):1043\u20131052. https:\/\/doi.org\/10.1038\/sj.onc.1208305","journal-title":"Oncogene"},{"issue":"Pt 18","key":"1892_CR20","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1242\/jcs.029256","volume":"121","author":"G Fitsialos","year":"2008","unstructured":"Fitsialos G, Bourget I, Augier S, Ginouves A, Rezzonico R, Odorisio T, Cianfarani F, Virolle T et al (2008) HIF1 transcription factor regulates laminin-332 expression and keratinocyte migration. J Cell Sci 121(Pt 18):2992\u20133001. https:\/\/doi.org\/10.1242\/jcs.029256","journal-title":"J Cell Sci"},{"issue":"49","key":"1892_CR21","doi-asserted-by":"publisher","first-page":"19611","DOI":"10.1073\/pnas.1117773108","volume":"108","author":"DR Wise","year":"2011","unstructured":"Wise DR, Ward PS, Shay JE, Cross JR, Gruber JJ, Sachdeva UM, Platt JM, DeMatteo RG et al (2011) Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci U S A 108(49):19611\u201319616. https:\/\/doi.org\/10.1073\/pnas.1117773108","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1892_CR22","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/84635","volume":"7","author":"SA Stacker","year":"2001","unstructured":"Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S et al (2001) VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7(2):186\u2013191. https:\/\/doi.org\/10.1038\/84635","journal-title":"Nat Med"},{"issue":"2","key":"1892_CR23","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1006\/excr.1993.1043","volume":"204","author":"MS Pepper","year":"1993","unstructured":"Pepper MS, Vassalli JD, Orci L, Montesano R (1993) Biphasic effect of transforming growth factor-beta 1 on in vitro angiogenesis. Exp Cell Res 204(2):356\u2013363. https:\/\/doi.org\/10.1006\/excr.1993.1043","journal-title":"Exp Cell Res"},{"issue":"1","key":"1892_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1083\/jcb.109.1.1","volume":"109","author":"DB Rifkin","year":"1989","unstructured":"Rifkin DB, Moscatelli D (1989) Recent developments in the cell biology of basic fibroblast growth factor. J Cell Biol 109(1):1\u20136. https:\/\/doi.org\/10.1083\/jcb.109.1.1","journal-title":"J Cell Biol"},{"issue":"5388","key":"1892_CR25","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1126\/science.282.5388.468","volume":"282","author":"C Suri","year":"1998","unstructured":"Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, Sato TN, Yancopoulos GD (1998) Increased vascularization in mice overexpressing angiopoietin-1. Science 282(5388):468\u2013471","journal-title":"Science"},{"issue":"21","key":"1892_CR26","first-page":"5300","volume":"53","author":"ME Gleave","year":"1993","unstructured":"Gleave ME, Hsieh JT, Wu HC, Hong SJ, Zhau HE, Guthrie PD, Chung LW (1993) Epidermal growth factor receptor-mediated autocrine and paracrine stimulation of human transitional cell carcinoma. Cancer Res 53(21):5300\u20135307","journal-title":"Cancer Res"},{"issue":"10","key":"1892_CR27","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1586\/14737175.8.10.1457","volume":"8","author":"SS Lakka","year":"2008","unstructured":"Lakka SS, Rao JS (2008) Antiangiogenic therapy in brain tumors. Expert Rev Neurother 8(10):1457\u20131473. https:\/\/doi.org\/10.1586\/14737175.8.10.1457","journal-title":"Expert Rev Neurother"},{"key":"1892_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2014.07.011","volume":"76","author":"H Hong","year":"2014","unstructured":"Hong H, Chen F, Zhang Y, Cai W (2014) New radiotracers for imaging of vascular targets in angiogenesis-related diseases. Adv Drug Deliv Rev 76:2\u201320. https:\/\/doi.org\/10.1016\/j.addr.2014.07.011","journal-title":"Adv Drug Deliv Rev"},{"issue":"8","key":"1892_CR29","doi-asserted-by":"publisher","first-page":"a005090","DOI":"10.1101\/cshperspect.a005090","volume":"3","author":"DR Senger","year":"2011","unstructured":"Senger DR, Davis GE (2011) Angiogenesis. Cold Spring Harb Perspect Biol 3(8):a005090. https:\/\/doi.org\/10.1101\/cshperspect.a005090","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"6","key":"1892_CR30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrd3455","volume":"10","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10(6):417\u2013427. https:\/\/doi.org\/10.1038\/nrd3455","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1892_CR31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.gde.2010.10.008","volume":"21","author":"K De Bock","year":"2011","unstructured":"De Bock K, Cauwenberghs S, Carmeliet P (2011) Vessel abnormalization: Another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr Opin Genet Dev 21(1):73\u201379. https:\/\/doi.org\/10.1016\/j.gde.2010.10.008","journal-title":"Curr Opin Genet Dev"},{"issue":"5","key":"1892_CR32","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.cell.2009.01.020","volume":"136","author":"M Mazzone","year":"2009","unstructured":"Mazzone M, Dettori D, de Oliveira RL, Loges S, Schmidt T, Jonckx B, Tian YM, Lanahan AA et al (2009) Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136(5):839\u2013851. https:\/\/doi.org\/10.1016\/j.cell.2009.01.020","journal-title":"Cell"},{"issue":"3","key":"1892_CR33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1055\/s-0030-1253454","volume":"36","author":"JA Nagy","year":"2010","unstructured":"Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF (2010) Heterogeneity of the tumor vasculature. Semin Thromb Hemost 36(3):321\u2013331. https:\/\/doi.org\/10.1055\/s-0030-1253454","journal-title":"Semin Thromb Hemost"},{"issue":"18","key":"1892_CR34","doi-asserted-by":"publisher","first-page":"7243","DOI":"10.1158\/0008-5472.CAN-09-0167","volume":"69","author":"C Folkins","year":"2009","unstructured":"Folkins C, Shaked Y, Man S, Tang T, Lee CR, Zhu Z, Hoffman RM, Kerbel RS (2009) Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res 69(18):7243\u20137251. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-0167","journal-title":"Cancer Res"},{"issue":"5","key":"1892_CR35","doi-asserted-by":"publisher","first-page":"C947","DOI":"10.1152\/ajpcell.00389.2001","volume":"282","author":"M Papetti","year":"2002","unstructured":"Papetti M, Herman IM (2002) Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 282(5):C947\u2013C970. https:\/\/doi.org\/10.1152\/ajpcell.00389.2001","journal-title":"Am J Physiol Cell Physiol"},{"issue":"5","key":"1892_CR36","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1073\/pnas.1018154108","volume":"108","author":"JW Baish","year":"2011","unstructured":"Baish JW, Stylianopoulos T, Lanning RM, Kamoun WS, Fukumura D, Munn LL, Jain RK (2011) Scaling rules for diffusive drug delivery in tumor and normal tissues. Proc Natl Acad Sci U S A 108(5):1799\u20131803. https:\/\/doi.org\/10.1073\/pnas.1018154108","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"46","key":"1892_CR37","doi-asserted-by":"publisher","first-page":"18632","DOI":"10.1073\/pnas.1318415110","volume":"110","author":"T Stylianopoulos","year":"2013","unstructured":"Stylianopoulos T, Jain RK (2013) Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci U S A 110(46):18632\u201318637. https:\/\/doi.org\/10.1073\/pnas.1318415110","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"1892_CR38","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/jnci\/djm135","volume":"99","author":"O Tredan","year":"2007","unstructured":"Tredan O, Galmarini CM, Patel K, Tannock IF (2007) Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99(19):1441\u20131454. https:\/\/doi.org\/10.1093\/jnci\/djm135","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"1892_CR39","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S1471-4914(01)02090-1","volume":"7","author":"GL Semenza","year":"2001","unstructured":"Semenza GL (2001) Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med 7(8):345\u2013350","journal-title":"Trends Mol Med"},{"issue":"8","key":"1892_CR40","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/07357907.2017.1364745","volume":"35","author":"DW Siemann","year":"2017","unstructured":"Siemann DW, Chaplin DJ, Horsman MR (2017) Realizing the potential of vascular targeted therapy: the rationale for combining vascular disrupting agents and anti-angiogenic agents to treat cancer. Cancer Investig 35(8):519\u2013534. https:\/\/doi.org\/10.1080\/07357907.2017.1364745","journal-title":"Cancer Investig"},{"issue":"22","key":"1892_CR41","doi-asserted-by":"publisher","first-page":"5612","DOI":"10.1158\/1078-0432.CCR-14-0834","volume":"20","author":"TT Batchelor","year":"2014","unstructured":"Batchelor TT, Reardon DA, de Groot JF, Wick W, Weller M (2014) Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res 20(22):5612\u20135619. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0834","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1892_CR42","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.18632\/oncotarget.659","volume":"3","author":"JA McCubrey","year":"2012","unstructured":"McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M et al (2012) Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 3(10):1068\u20131111. https:\/\/doi.org\/10.18632\/oncotarget.659","journal-title":"Oncotarget"},{"issue":"11","key":"1892_CR43","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2176\/nmc.ra2013-0200","volume":"53","author":"M Onishi","year":"2013","unstructured":"Onishi M, Kurozumi K, Ichikawa T, Date I (2013) Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme. Neurol Med Chir (Tokyo) 53(11):755\u2013763","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"3","key":"1892_CR44","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3109\/0284186X.2014.951492","volume":"54","author":"L Sooman","year":"2015","unstructured":"Sooman L, Freyhult E, Jaiswal A, Navani S, Edqvist PH, Ponten F, Tchougounova E, Smits A et al (2015) FGF2 as a potential prognostic biomarker for proneural glioma patients. Acta Oncol 54(3):385\u2013394. https:\/\/doi.org\/10.3109\/0284186X.2014.951492","journal-title":"Acta Oncol"},{"issue":"6","key":"1892_CR45","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1158\/2159-8290.CD-11-0218","volume":"1","author":"PK Vogt","year":"2011","unstructured":"Vogt PK, Hart JR (2011) PI3K and STAT3: a new alliance. Cancer Discov 1(6):481\u2013486. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0218","journal-title":"Cancer Discov"},{"issue":"6","key":"1892_CR46","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.molmed.2011.01.011","volume":"17","author":"RY Bai","year":"2011","unstructured":"Bai RY, Staedtke V, Riggins GJ (2011) Molecular targeting of glioblastoma: drug discovery and therapies. Trends Mol Med 17(6):301\u2013312. https:\/\/doi.org\/10.1016\/j.molmed.2011.01.011","journal-title":"Trends Mol Med"},{"issue":"8","key":"1892_CR47","doi-asserted-by":"publisher","first-page":"712","DOI":"10.2174\/187152011797378643","volume":"11","author":"AG Linkous","year":"2011","unstructured":"Linkous AG, Yazlovitskaya EM (2011) Angiogenesis in glioblastoma multiforme: navigating the maze. Anti Cancer Agents Med Chem 11(8):712\u2013718","journal-title":"Anti Cancer Agents Med Chem"},{"issue":"11","key":"1892_CR48","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/nbt1101-1029","volume":"19","author":"TP Richardson","year":"2001","unstructured":"Richardson TP, Peters MC, Ennett AB, Mooney DJ (2001) Polymeric system for dual growth factor delivery. Nat Biotechnol 19(11):1029\u20131034. https:\/\/doi.org\/10.1038\/nbt1101-1029","journal-title":"Nat Biotechnol"},{"issue":"5","key":"1892_CR49","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/nm848","volume":"9","author":"R Cao","year":"2003","unstructured":"Cao R, Brakenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, Leboulch P, Cao Y (2003) Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 9(5):604\u2013613. https:\/\/doi.org\/10.1038\/nm848","journal-title":"Nat Med"},{"issue":"1","key":"1892_CR50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1096\/fasebj.13.1.9","volume":"13","author":"G Neufeld","year":"1999","unstructured":"Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13(1):9\u201322","journal-title":"FASEB J"},{"issue":"5","key":"1892_CR51","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/87904","volume":"7","author":"P Carmeliet","year":"2001","unstructured":"Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F et al (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7(5):575\u2013583. https:\/\/doi.org\/10.1038\/87904","journal-title":"Nat Med"},{"issue":"17","key":"1892_CR52","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.3748\/wjg.v10.i17.2524","volume":"10","author":"XT Sun","year":"2004","unstructured":"Sun XT, Ding YT, Yan XG, Wu LY, Li Q, Cheng N, Qiu YD, Zhang MY (2004) Angiogenic synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in an in vitro quantitative microcarrier-based three-dimensional fibrin angiogenesis system. World J Gastroenterol 10(17):2524\u20132528. https:\/\/doi.org\/10.3748\/wjg.v10.i17.2524","journal-title":"World J Gastroenterol"},{"issue":"6","key":"1892_CR53","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1161\/01.RES.0000259593.07661.1e","volume":"100","author":"L Lamalice","year":"2007","unstructured":"Lamalice L, Le Boeuf F, Huot J (2007) Endothelial cell migration during angiogenesis. Circ Res 100(6):782\u2013794. https:\/\/doi.org\/10.1161\/01.RES.0000259593.07661.1e","journal-title":"Circ Res"},{"issue":"2","key":"1892_CR54","first-page":"368","volume":"146","author":"E Hatva","year":"1995","unstructured":"Hatva E, Kaipainen A, Mentula P, Jaaskelainen J, Paetau A, Haltia M, Alitalo K (1995) Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. Am J Pathol 146(2):368\u2013378","journal-title":"Am J Pathol"},{"issue":"5","key":"1892_CR55","first-page":"1189","volume":"55","author":"K Samoto","year":"1995","unstructured":"Samoto K, Ikezaki K, Ono M, Shono T, Kohno K, Kuwano M, Fukui M (1995) Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 55(5):1189\u20131193","journal-title":"Cancer Res"},{"issue":"3","key":"1892_CR56","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/glia.440150313","volume":"15","author":"KH Plate","year":"1995","unstructured":"Plate KH, Risau W (1995) Angiogenesis in malignant gliomas. Glia 15(3):339\u2013347. https:\/\/doi.org\/10.1002\/glia.440150313","journal-title":"Glia"},{"issue":"6","key":"1892_CR57","first-page":"913","volume":"2","author":"H Phillips","year":"1993","unstructured":"Phillips H, Armani M, Stavrou D, Ferrara N, Westphal M (1993) Intense focal expression of vascular endothelial growth-factor messenger-RNA in human intracranial neoplasms - association with regions of necrosis. Int J Oncol 2(6):913\u2013919","journal-title":"Int J Oncol"},{"issue":"6398","key":"1892_CR58","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/359845a0","volume":"359","author":"KH Plate","year":"1992","unstructured":"Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359(6398):845\u2013848. https:\/\/doi.org\/10.1038\/359845a0","journal-title":"Nature"},{"issue":"6","key":"1892_CR59","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1634\/theoncologist.2008-0272","volume":"14","author":"AS Chi","year":"2009","unstructured":"Chi AS, Sorensen AG, Jain RK, Batchelor TT (2009) Angiogenesis as a therapeutic target in malignant gliomas. Oncologist 14(6):621\u2013636. https:\/\/doi.org\/10.1634\/theoncologist.2008-0272","journal-title":"Oncologist"},{"issue":"2","key":"1892_CR60","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s007010170122","volume":"143","author":"Y Yao","year":"2001","unstructured":"Yao Y, Kubota T, Sato K, Kitai R, Takeuchi H, Arishima H (2001) Prognostic value of vascular endothelial growth factor and its receptors Flt-1 and Flk-1 in astrocytic tumours. Acta Neurochir 143(2):159\u2013166","journal-title":"Acta Neurochir"},{"issue":"3","key":"1892_CR61","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S1040-8428(00)00062-7","volume":"34","author":"P Gerwins","year":"2000","unstructured":"Gerwins P, Skoldenberg E, Claesson-Welsh L (2000) Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit Rev Oncol Hematol 34(3):185\u2013194","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"1892_CR62","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1074\/jbc.270.5.2360","volume":"270","author":"G Sa","year":"1995","unstructured":"Sa G, Murugesan G, Jaye M, Ivashchenko Y, Fox PL (1995) Activation of cytosolic phospholipase A2 by basic fibroblast growth factor via a p42 mitogen-activated protein kinase-dependent phosphorylation pathway in endothelial cells. J Biol Chem 270(5):2360\u20132366. https:\/\/doi.org\/10.1074\/jbc.270.5.2360","journal-title":"J Biol Chem"},{"issue":"3","key":"1892_CR63","first-page":"383","volume":"7","author":"S Kanda","year":"1996","unstructured":"Kanda S, Landgren E, Ljungstrom M, Claesson-Welsh L (1996) Fibroblast growth factor receptor 1-induced differentiation of endothelial cell line established from tsA58 large T transgenic mice. Cell Growth Differ 7(3):383\u2013395","journal-title":"Cell Growth Differ"},{"issue":"11","key":"1892_CR64","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1002\/1097-0142(19921201)70:11<2673::AID-CNCR2820701118>3.0.CO;2-F","volume":"70","author":"S Brem","year":"1992","unstructured":"Brem S, Tsanaclis AM, Gately S, Gross JL, Herblin WF (1992) Immunolocalization of basic fibroblast growth factor to the microvasculature of human brain tumors. Cancer 70(11):2673\u20132680","journal-title":"Cancer"},{"issue":"5","key":"1892_CR65","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3171\/jns.1992.76.5.0792","volume":"76","author":"JA Takahashi","year":"1992","unstructured":"Takahashi JA, Fukumoto M, Igarashi K, Oda Y, Kikuchi H, Hatanaka M (1992) Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J Neurosurg 76(5):792\u2013798. https:\/\/doi.org\/10.3171\/jns.1992.76.5.0792","journal-title":"J Neurosurg"},{"issue":"22","key":"1892_CR66","first-page":"7393","volume":"50","author":"D Zagzag","year":"1990","unstructured":"Zagzag D, Miller DC, Sato Y, Rifkin DB, Burstein DE (1990) Immunohistochemical localization of basic fibroblast growth factor in astrocytomas. Cancer Res 50(22):7393\u20137398","journal-title":"Cancer Res"},{"issue":"6","key":"1892_CR67","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.3171\/jns.1995.82.6.1044","volume":"82","author":"AC Stan","year":"1995","unstructured":"Stan AC, Nemati MN, Pietsch T, Walter GF, Dietz H (1995) In vivo inhibition of angiogenesis and growth of the human U-87 malignant glial tumor by treatment with an antibody against basic fibroblast growth factor. J Neurosurg 82(6):1044\u20131052. https:\/\/doi.org\/10.3171\/jns.1995.82.6.1044","journal-title":"J Neurosurg"},{"issue":"4","key":"1892_CR68","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.cytogfr.2004.03.007","volume":"15","author":"L Fredriksson","year":"2004","unstructured":"Fredriksson L, Li H, Eriksson U (2004) The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 15(4):197\u2013204. https:\/\/doi.org\/10.1016\/j.cytogfr.2004.03.007","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1\u20132","key":"1892_CR69","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S0169-328X(03)00085-8","volume":"113","author":"O Renner","year":"2003","unstructured":"Renner O, Tsimpas A, Kostin S, Valable S, Petit E, Schaper W, Marti HH (2003) Time- and cell type-specific induction of platelet-derived growth factor receptor-beta during cerebral ischemia. Brain Res Mol Brain Res 113(1\u20132):44\u201351","journal-title":"Brain Res Mol Brain Res"},{"issue":"7070","key":"1892_CR70","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nature04483","volume":"438","author":"N Ferrara","year":"2005","unstructured":"Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438(7070):967\u2013974. https:\/\/doi.org\/10.1038\/nature04483","journal-title":"Nature"},{"issue":"10","key":"1892_CR71","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1046\/j.1365-2362.2003.01245.x","volume":"33","author":"D Ribatti","year":"2003","unstructured":"Ribatti D, Vacca A, Roccaro AM, Crivellato E, Presta M (2003) Erythropoietin as an angiogenic factor. Eur J Clin Investig 33(10):891\u2013896","journal-title":"Eur J Clin Investig"},{"issue":"5","key":"1892_CR72","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1172\/JCI13055","volume":"109","author":"K Sasaki","year":"2002","unstructured":"Sasaki K, Murohara T, Ikeda H, Sugaya T, Shimada T, Shintani S, Imaizumi T (2002) Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. J Clin Invest 109(5):603\u2013611. https:\/\/doi.org\/10.1172\/JCI13055","journal-title":"J Clin Invest"},{"issue":"20","key":"1892_CR73","doi-asserted-by":"publisher","first-page":"7748","DOI":"10.1073\/pnas.85.20.7748","volume":"85","author":"M Hermansson","year":"1988","unstructured":"Hermansson M, Nister M, Betsholtz C, Heldin CH, Westermark B, Funa K (1988) Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation. Proc Natl Acad Sci U S A 85(20):7748\u20137752. https:\/\/doi.org\/10.1073\/pnas.85.20.7748","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"1892_CR74","first-page":"3729","volume":"62","author":"NA Lokker","year":"2002","unstructured":"Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA (2002) Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 62(13):3729\u20133735","journal-title":"Cancer Res"},{"issue":"6","key":"1892_CR75","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/sj.bjc.6605225","volume":"101","author":"O Martinho","year":"2009","unstructured":"Martinho O, Longatto-Filho A, Lambros MB, Martins A, Pinheiro C, Silva A, Pardal F, Amorim J et al (2009) Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. Br J Cancer 101(6):973\u2013982. https:\/\/doi.org\/10.1038\/sj.bjc.6605225","journal-title":"Br J Cancer"},{"issue":"8","key":"1892_CR76","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/glia.20334","volume":"53","author":"A Farin","year":"2006","unstructured":"Farin A, Suzuki SO, Weiker M, Goldman JE, Bruce JN, Canoll P (2006) Transplanted glioma cells migrate and proliferate on host brain vasculature: a dynamic analysis. Glia 53(8):799\u2013808. https:\/\/doi.org\/10.1002\/glia.20334","journal-title":"Glia"},{"issue":"1","key":"1892_CR77","doi-asserted-by":"publisher","first-page":"15271","DOI":"10.1038\/s41598-017-15045-w","volume":"7","author":"IG Cantanhede","year":"2017","unstructured":"Cantanhede IG, de Oliveira JRM (2017) PDGF family expression in glioblastoma multiforme: data compilation from Ivy glioblastoma atlas project database. Sci Rep 7(1):15271. https:\/\/doi.org\/10.1038\/s41598-017-15045-w","journal-title":"Sci Rep"},{"issue":"33","key":"1892_CR78","doi-asserted-by":"publisher","first-page":"53047","DOI":"10.18632\/oncotarget.10132","volume":"7","author":"C Cenciarelli","year":"2016","unstructured":"Cenciarelli C, Marei HE, Felsani A, Casalbore P, Sica G, Puglisi MA, Cameron AJ, Olivi A et al (2016) PDGFRalpha depletion attenuates glioblastoma stem cells features by modulation of STAT3, RB1 and multiple oncogenic signals. Oncotarget 7(33):53047\u201353063. https:\/\/doi.org\/10.18632\/oncotarget.10132","journal-title":"Oncotarget"},{"issue":"11","key":"1892_CR79","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1101\/gad.193565.112","volume":"26","author":"Y Kim","year":"2012","unstructured":"Kim Y, Kim E, Wu Q, Guryanova O, Hitomi M, Lathia JD, Serwanski D, Sloan AE et al (2012) Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. Genes Dev 26(11):1247\u20131262. https:\/\/doi.org\/10.1101\/gad.193565.112","journal-title":"Genes Dev"},{"issue":"4","key":"1892_CR80","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nrc779","volume":"2","author":"L Trusolino","year":"2002","unstructured":"Trusolino L, Comoglio PM (2002) Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2(4):289\u2013300. https:\/\/doi.org\/10.1038\/nrc779","journal-title":"Nat Rev Cancer"},{"issue":"22","key":"1892_CR81","doi-asserted-by":"publisher","first-page":"12718","DOI":"10.1073\/pnas.2135113100","volume":"100","author":"YW Zhang","year":"2003","unstructured":"Zhang YW, Su Y, Volpert OV, Vande Woude GF (2003) Hepatocyte growth factor\/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A 100(22):12718\u201312723. https:\/\/doi.org\/10.1073\/pnas.2135113100","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1892_CR82","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1161\/01.ATV.0000048701.86621.D0","volume":"23","author":"S Sengupta","year":"2003","unstructured":"Sengupta S, Gherardi E, Sellers LA, Wood JM, Sasisekharan R, Fan TP (2003) Hepatocyte growth factor\/scatter factor can induce angiogenesis independently of vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 23(1):69\u201375","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"1892_CR83","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1215\/S1152851705000050","volume":"7","author":"R Abounader","year":"2005","unstructured":"Abounader R, Laterra J (2005) Scatter factor\/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro-Oncology 7(4):436\u2013451. https:\/\/doi.org\/10.1215\/S1152851705000050","journal-title":"Neuro-Oncology"},{"issue":"1","key":"1892_CR84","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1096\/fj.01-0421fje","volume":"16","author":"R Abounader","year":"2002","unstructured":"Abounader R, Lal B, Luddy C, Koe G, Davidson B, Rosen EM, Laterra J (2002) In vivo targeting of SF\/HGF and c-met expression via U1snRNA\/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J 16(1):108\u2013110. https:\/\/doi.org\/10.1096\/fj.01-0421fje","journal-title":"FASEB J"},{"issue":"7","key":"1892_CR85","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.21873\/anticanres.11767","volume":"37","author":"T Okuda","year":"2017","unstructured":"Okuda T, Tasaki T, Nakata S, Yamashita K, Yoshioka H, Izumoto S, Kato A, Fujita M (2017) Efficacy of combination therapy with MET and VEGF inhibitors for MET-overexpressing glioblastoma. Anticancer Res 37(7):3871\u20133876. https:\/\/doi.org\/10.21873\/anticanres.11767","journal-title":"Anticancer Res"},{"issue":"1","key":"1892_CR86","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00441-003-0749-6","volume":"314","author":"G Thurston","year":"2003","unstructured":"Thurston G (2003) Role of angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res 314(1):61\u201368. https:\/\/doi.org\/10.1007\/s00441-003-0749-6","journal-title":"Cell Tissue Res"},{"issue":"5322","key":"1892_CR87","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1126\/science.277.5322.55","volume":"277","author":"PC Maisonpierre","year":"1997","unstructured":"Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J et al (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277(5322):55\u201360","journal-title":"Science"},{"issue":"20","key":"1892_CR88","doi-asserted-by":"publisher","first-page":"20126","DOI":"10.1074\/jbc.M500292200","volume":"280","author":"KT Kim","year":"2005","unstructured":"Kim KT, Choi HH, Steinmetz MO, Maco B, Kammerer RA, Ahn SY, Kim HZ, Lee GM et al (2005) Oligomerization and multimerization are critical for angiopoietin-1 to bind and phosphorylate Tie2. J Biol Chem 280(20):20126\u201320131. https:\/\/doi.org\/10.1074\/jbc.M500292200","journal-title":"J Biol Chem"},{"issue":"17","key":"1892_CR89","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1158\/0008-5472.CAN-04-1054","volume":"64","author":"Y Xu","year":"2004","unstructured":"Xu Y, Liu YJ, Yu Q (2004) Angiopoietin-3 inhibits pulmonary metastasis by inhibiting tumor angiogenesis. Cancer Res 64(17):6119\u20136126. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-1054","journal-title":"Cancer Res"},{"key":"1892_CR90","doi-asserted-by":"publisher","unstructured":"Cam M, Charan M, Welker AM, Dravid P, Studebaker AW, Leonard JR, Pierson CR, Nakano I et al (2019) DeltaNp73\/ETS2 complex drives glioblastoma pathogenesis- targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma. Neuro-Oncology. https:\/\/doi.org\/10.1093\/neuonc\/noz190","DOI":"10.1093\/neuonc\/noz190"},{"issue":"6","key":"1892_CR91","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/labinvest.3780088","volume":"80","author":"D Zagzag","year":"2000","unstructured":"Zagzag D, Amirnovin R, Greco MA, Yee H, Holash J, Wiegand SJ, Zabski S, Yancopoulos GD et al (2000) Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Investig 80(6):837\u2013849","journal-title":"Lab Investig"},{"issue":"18","key":"1892_CR92","doi-asserted-by":"publisher","first-page":"7283","DOI":"10.1158\/0008-5472.CAN-09-4125","volume":"70","author":"MK Brunckhorst","year":"2010","unstructured":"Brunckhorst MK, Wang H, Lu R, Yu Q (2010) Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis. Cancer Res 70(18):7283\u20137293. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-4125","journal-title":"Cancer Res"},{"issue":"12","key":"1892_CR93","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1158\/1541-7786.MCR-06-0184","volume":"4","author":"OH Lee","year":"2006","unstructured":"Lee OH, Xu J, Fueyo J, Fuller GN, Aldape KD, Alonso MM, Piao Y, Liu TJ et al (2006) Expression of the receptor tyrosine kinase Tie2 in neoplastic glial cells is associated with integrin beta1-dependent adhesion to the extracellular matrix. Mol Cancer Res 4(12):915\u2013926. https:\/\/doi.org\/10.1158\/1541-7786.MCR-06-0184","journal-title":"Mol Cancer Res"},{"issue":"9","key":"1892_CR94","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/sj.onc.1210731","volume":"27","author":"OH Lee","year":"2008","unstructured":"Lee OH, Xu J, Fueyo J, Alonso MM, Liu D, Martin V, Jiang H, Piao Y et al (2008) Angiopoietin-2 decreases vascular endothelial growth factor expression by modulating HIF-1 alpha levels in gliomas. Oncogene 27(9):1310\u20131314. https:\/\/doi.org\/10.1038\/sj.onc.1210731","journal-title":"Oncogene"},{"issue":"1","key":"1892_CR95","doi-asserted-by":"publisher","first-page":"39","DOI":"10.15252\/emmm.201505505","volume":"8","author":"A Scholz","year":"2016","unstructured":"Scholz A, Harter PN, Cremer S, Yalcin BH, Gurnik S, Yamaji M, Di Tacchio M, Sommer K et al (2016) Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. EMBO Mol Med 8(1):39\u201357. https:\/\/doi.org\/10.15252\/emmm.201505505","journal-title":"EMBO Mol Med"},{"issue":"2","key":"1892_CR96","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0968-0004(99)01519-4","volume":"25","author":"P ten Dijke","year":"2000","unstructured":"ten Dijke P, Miyazono K, Heldin CH (2000) Signaling inputs converge on nuclear effectors in TGF-beta signaling. Trends Biochem Sci 25(2):64\u201370","journal-title":"Trends Biochem Sci"},{"issue":"10","key":"1892_CR97","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1002\/ijc.23113","volume":"121","author":"SK Leivonen","year":"2007","unstructured":"Leivonen SK, Kahari VM (2007) Transforming growth factor-beta signaling in cancer invasion and metastasis. Int J Cancer 121(10):2119\u20132124. https:\/\/doi.org\/10.1002\/ijc.23113","journal-title":"Int J Cancer"},{"key":"1892_CR98","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0065-2776(00)75003-6","volume":"75","author":"K Miyazono","year":"2000","unstructured":"Miyazono K, ten Dijke P, Heldin CH (2000) TGF-beta signaling by Smad proteins. Adv Immunol 75:115\u2013157","journal-title":"Adv Immunol"},{"issue":"7","key":"1892_CR99","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1093\/emboj\/21.7.1743","volume":"21","author":"MJ Goumans","year":"2002","unstructured":"Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P (2002) Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 21(7):1743\u20131753. https:\/\/doi.org\/10.1093\/emboj\/21.7.1743","journal-title":"EMBO J"},{"issue":"2","key":"1892_CR100","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1083\/jcb.105.2.957","volume":"105","author":"O Saksela","year":"1987","unstructured":"Saksela O, Moscatelli D, Rifkin DB (1987) The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells. J Cell Biol 105(2):957\u2013963. https:\/\/doi.org\/10.1083\/jcb.105.2.957","journal-title":"J Cell Biol"},{"issue":"46","key":"1892_CR101","doi-asserted-by":"publisher","first-page":"17260","DOI":"10.1073\/pnas.0605556103","volume":"103","author":"G Ferrari","year":"2006","unstructured":"Ferrari G, Pintucci G, Seghezzi G, Hyman K, Galloway AC, Mignatti P (2006) VEGF, a prosurvival factor, acts in concert with TGF-beta1 to induce endothelial cell apoptosis. Proc Natl Acad Sci U S A 103(46):17260\u201317265. https:\/\/doi.org\/10.1073\/pnas.0605556103","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1892_CR102","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1006\/bbrc.2000.2176","volume":"268","author":"M Platten","year":"2000","unstructured":"Platten M, Wick W, Wild-Bode C, Aulwurm S, Dichgans J, Weller M (2000) Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via up-regulation of alpha(V)beta(3) integrin expression. Biochem Biophys Res Commun 268(2):607\u2013611. https:\/\/doi.org\/10.1006\/bbrc.2000.2176","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"1892_CR103","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.2174\/138920111798808338","volume":"12","author":"LA van Meeteren","year":"2011","unstructured":"van Meeteren LA, Goumans MJ, ten Dijke P (2011) TGF-beta receptor signaling pathways in angiogenesis; emerging targets for anti-angiogenesis therapy. Curr Pharm Biotechnol 12(12):2108\u20132120","journal-title":"Curr Pharm Biotechnol"},{"issue":"2","key":"1892_CR104","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ccr.2006.11.023","volume":"11","author":"A Bruna","year":"2007","unstructured":"Bruna A, Darken RS, Rojo F, Ocana A, Penuelas S, Arias A, Paris R, Tortosa A et al (2007) High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 11(2):147\u2013160. https:\/\/doi.org\/10.1016\/j.ccr.2006.11.023","journal-title":"Cancer Cell"},{"issue":"2","key":"1892_CR105","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.intimp.2012.12.002","volume":"15","author":"XJ Yang","year":"2013","unstructured":"Yang XJ, Chen GL, Yu SC, Xu C, Xin YH, Li TT, Shi Y, Gu A et al (2013) TGF-beta1 enhances tumor-induced angiogenesis via JNK pathway and macrophage infiltration in an improved zebrafish embryo\/xenograft glioma model. Int Immunopharmacol 15(2):191\u2013198. https:\/\/doi.org\/10.1016\/j.intimp.2012.12.002","journal-title":"Int Immunopharmacol"},{"issue":"26","key":"1892_CR106","doi-asserted-by":"publisher","first-page":"22480","DOI":"10.18632\/oncotarget.4310","volume":"6","author":"S Krishnan","year":"2015","unstructured":"Krishnan S, Szabo E, Burghardt I, Frei K, Tabatabai G, Weller M (2015) Modulation of cerebral endothelial cell function by TGF-beta in glioblastoma: VEGF-dependent angiogenesis versus endothelial mesenchymal transition. Oncotarget 6(26):22480\u201322495. https:\/\/doi.org\/10.18632\/oncotarget.4310","journal-title":"Oncotarget"},{"issue":"1","key":"1892_CR107","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cell.2013.02.021","volume":"153","author":"L Cheng","year":"2013","unstructured":"Cheng L, Huang Z, Zhou W, Wu Q, Donnola S, Liu JK, Fang X, Sloan AE et al (2013) Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153(1):139\u2013152. https:\/\/doi.org\/10.1016\/j.cell.2013.02.021","journal-title":"Cell"},{"issue":"3","key":"1892_CR108","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ejca.2005.11.010","volume":"42","author":"CF Chantrain","year":"2006","unstructured":"Chantrain CF, Henriet P, Jodele S, Emonard H, Feron O, Courtoy PJ, DeClerck YA, Marbaix E (2006) Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases. Eur J Cancer 42(3):310\u2013318. https:\/\/doi.org\/10.1016\/j.ejca.2005.11.010","journal-title":"Eur J Cancer"},{"issue":"2","key":"1892_CR109","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/BF02483449","volume":"20","author":"M Wang","year":"2003","unstructured":"Wang M, Wang T, Liu S, Yoshida D, Teramoto A (2003) The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathol 20(2):65\u201372","journal-title":"Brain Tumor Pathol"},{"issue":"4","key":"1892_CR110","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1750-3639.2005.tb00118.x","volume":"15","author":"SS Lakka","year":"2005","unstructured":"Lakka SS, Gondi CS, Rao JS (2005) Proteases and glioma angiogenesis. Brain Pathol 15(4):327\u2013341","journal-title":"Brain Pathol"},{"issue":"10","key":"1892_CR111","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/35036374","volume":"2","author":"G Bergers","year":"2000","unstructured":"Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P et al (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2(10):737\u2013744. https:\/\/doi.org\/10.1038\/35036374","journal-title":"Nat Cell Biol"},{"issue":"5","key":"1892_CR112","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"issue":"2","key":"1892_CR113","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s13311-016-0510-y","volume":"14","author":"N Wang","year":"2017","unstructured":"Wang N, Jain RK, Batchelor TT (2017) New directions in anti-angiogenic therapy for glioblastoma. Neurotherapeutics 14(2):321\u2013332. https:\/\/doi.org\/10.1007\/s13311-016-0510-y","journal-title":"Neurotherapeutics"},{"issue":"16","key":"1892_CR114","doi-asserted-by":"publisher","first-page":"8502","DOI":"10.1073\/pnas.93.16.8502","volume":"93","author":"SY Cheng","year":"1996","unstructured":"Cheng SY, Huang HJ, Nagane M, Ji XD, Wang D, Shih CC, Arap W, Huang CM et al (1996) Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A 93(16):8502\u20138507. https:\/\/doi.org\/10.1073\/pnas.93.16.8502","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1892_CR115","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S0002-9440(10)65173-5","volume":"155","author":"AJ Maniotis","year":"1999","unstructured":"Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, Trent JM, Meltzer PS et al (1999) Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155(3):739\u2013752. https:\/\/doi.org\/10.1016\/S0002-9440(10)65173-5","journal-title":"Am J Pathol"},{"issue":"1","key":"1892_CR116","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s12032-010-9765-z","volume":"29","author":"Y Chen","year":"2012","unstructured":"Chen Y, Jing Z, Luo C, Zhuang M, Xia J, Chen Z, Wang Y (2012) Vasculogenic mimicry-potential target for glioblastoma therapy: an in vitro and in vivo study. Med Oncol 29(1):324\u2013331. https:\/\/doi.org\/10.1007\/s12032-010-9765-z","journal-title":"Med Oncol"},{"key":"1892_CR117","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40364-015-0034-3","volume":"3","author":"JM Mao","year":"2015","unstructured":"Mao JM, Liu J, Guo G, Mao XG, Li CX (2015) Glioblastoma vasculogenic mimicry: signaling pathways progression and potential anti-angiogenesis targets. Biomarker Res 3:8. https:\/\/doi.org\/10.1186\/s40364-015-0034-3","journal-title":"Biomarker Res"},{"issue":"3","key":"1892_CR118","doi-asserted-by":"publisher","first-page":"e57188","DOI":"10.1371\/journal.pone.0057188","volume":"8","author":"X Yao","year":"2013","unstructured":"Yao X, Ping Y, Liu Y, Chen K, Yoshimura T, Liu M, Gong W, Chen C et al (2013) Vascular endothelial growth factor receptor 2 (VEGFR-2) plays a key role in vasculogenic mimicry formation, neovascularization and tumor initiation by glioma stem-like cells. PLoS One 8(3):e57188. https:\/\/doi.org\/10.1371\/journal.pone.0057188","journal-title":"PLoS One"},{"issue":"2","key":"1892_CR119","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.canlet.2013.07.028","volume":"341","author":"SH Kim","year":"2013","unstructured":"Kim SH, Wang D, Park YY, Katoh H, Margalit O, Sheffer M, Wu H, Holla VR et al (2013) HIG2 promotes colorectal cancer progression via hypoxia-dependent and independent pathways. Cancer Lett 341(2):159\u2013165. https:\/\/doi.org\/10.1016\/j.canlet.2013.07.028","journal-title":"Cancer Lett"},{"issue":"30","key":"1892_CR120","doi-asserted-by":"publisher","first-page":"47808","DOI":"10.18632\/oncotarget.10029","volume":"7","author":"XG Mao","year":"2016","unstructured":"Mao XG, Wang C, Liu DY, Zhang X, Wang L, Yan M, Zhang W, Zhu J et al (2016) Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma. Oncotarget 7(30):47808\u201347820. https:\/\/doi.org\/10.18632\/oncotarget.10029","journal-title":"Oncotarget"},{"issue":"24","key":"1892_CR121","doi-asserted-by":"publisher","first-page":"8228","DOI":"10.1158\/1078-0432.CCR-08-1329","volume":"14","author":"M Abou-Ghazal","year":"2008","unstructured":"Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong LY, Fuller GN, Hiraoka N et al (2008) The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res 14(24):8228\u20138235. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1329","journal-title":"Clin Cancer Res"},{"issue":"13","key":"1892_CR122","doi-asserted-by":"publisher","first-page":"7319","DOI":"10.1073\/pnas.131568898","volume":"98","author":"T Bowman","year":"2001","unstructured":"Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, Irby R, Yeatman T et al (2001) Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A 98(13):7319\u20137324. https:\/\/doi.org\/10.1073\/pnas.131568898","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"1892_CR123","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.18632\/oncotarget.663","volume":"3","author":"J de Groot","year":"2012","unstructured":"de Groot J, Liang J, Kong LY, Wei J, Piao Y, Fuller G, Qiao W, Heimberger AB (2012) Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma. Oncotarget 3(9):1036\u20131048. https:\/\/doi.org\/10.18632\/oncotarget.663","journal-title":"Oncotarget"},{"issue":"5","key":"1892_CR124","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3892\/or.2014.3454","volume":"32","author":"M Huang","year":"2014","unstructured":"Huang M, Ke Y, Sun X, Yu L, Yang Z, Zhang Y, Du M, Wang J et al (2014) Mammalian target of rapamycin signaling is involved in the vasculogenic mimicry of glioma via hypoxia-inducible factor-1alpha. Oncol Rep 32(5):1973\u20131980. https:\/\/doi.org\/10.3892\/or.2014.3454","journal-title":"Oncol Rep"},{"issue":"24","key":"1892_CR125","doi-asserted-by":"publisher","first-page":"7261","DOI":"10.1158\/1078-0432.CCR-06-0874","volume":"12","author":"MK Nicholas","year":"2006","unstructured":"Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R (2006) Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 12(24):7261\u20137270. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0874","journal-title":"Clin Cancer Res"},{"key":"1892_CR126","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2407-14-17","volume":"14","author":"EJ Choi","year":"2014","unstructured":"Choi EJ, Cho BJ, Lee DJ, Hwang YH, Chun SH, Kim HH, Kim IA (2014) Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases. BMC Cancer 14:17. https:\/\/doi.org\/10.1186\/1471-2407-14-17","journal-title":"BMC Cancer"},{"issue":"29","key":"1892_CR127","doi-asserted-by":"publisher","first-page":"24821","DOI":"10.1074\/jbc.M111.334540","volume":"287","author":"R Francescone","year":"2012","unstructured":"Francescone R, Scully S, Bentley B, Yan W, Taylor SL, Oh D, Moral L, Shao R (2012) Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation. J Biol Chem 287(29):24821\u201324831. https:\/\/doi.org\/10.1074\/jbc.M111.334540","journal-title":"J Biol Chem"},{"issue":"19","key":"1892_CR128","doi-asserted-by":"publisher","first-page":"9021","DOI":"10.1158\/0008-5472.CAN-04-4095","volume":"65","author":"D Escuin","year":"2005","unstructured":"Escuin D, Kline ER, Giannakakou P (2005) Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res 65(19):9021\u20139028. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-4095","journal-title":"Cancer Res"},{"issue":"10","key":"1892_CR129","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1080\/01616412.2016.1211231","volume":"38","author":"KJ Park","year":"2016","unstructured":"Park KJ, Yu MO, Park DH, Park JY, Chung YG, Kang SH (2016) Role of vincristine in the inhibition of angiogenesis in glioblastoma. Neurol Res 38(10):871\u2013879. https:\/\/doi.org\/10.1080\/01616412.2016.1211231","journal-title":"Neurol Res"},{"issue":"4","key":"1892_CR130","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/s0092-8674(00)80674-1","volume":"100","author":"A Di Cristofano","year":"2000","unstructured":"Di Cristofano A, Pandolfi PP (2000) The multiple roles of PTEN in tumor suppression. Cell 100(4):387\u2013390. https:\/\/doi.org\/10.1016\/s0092-8674(00)80674-1","journal-title":"Cell"},{"issue":"31","key":"1892_CR131","doi-asserted-by":"publisher","first-page":"31050","DOI":"10.18632\/oncotarget.2910","volume":"6","author":"T Kessler","year":"2015","unstructured":"Kessler T, Sahm F, Blaes J, Osswald M, Rubmann P, Milford D, Urban S, Jestaedt L et al (2015) Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma. Oncotarget 6(31):31050\u201331068. https:\/\/doi.org\/10.18632\/oncotarget.2910","journal-title":"Oncotarget"},{"issue":"6","key":"1892_CR132","doi-asserted-by":"publisher","first-page":"667","DOI":"10.4155\/tde.13.39","volume":"4","author":"RJ Ju","year":"2013","unstructured":"Ju RJ, Mu LM, Lu WL (2013) Targeting drug delivery systems for circumventing multidrug resistance of cancers. Ther Deliv 4(6):667\u2013671. https:\/\/doi.org\/10.4155\/tde.13.39","journal-title":"Ther Deliv"},{"issue":"21","key":"1892_CR133","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1016\/j.biomaterials.2014.03.049","volume":"35","author":"XY Li","year":"2014","unstructured":"Li XY, Zhao Y, Sun MG, Shi JF, Ju RJ, Zhang CX, Li XT, Zhao WY et al (2014) Multifunctional liposomes loaded with paclitaxel and artemether for treatment of invasive brain glioma. Biomaterials 35(21):5591\u20135604. https:\/\/doi.org\/10.1016\/j.biomaterials.2014.03.049","journal-title":"Biomaterials"},{"issue":"5","key":"1892_CR134","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","volume":"27","author":"TN Kreisl","year":"2009","unstructured":"Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740\u2013745. https:\/\/doi.org\/10.1200\/JCO.2008.16.3055","journal-title":"J Clin Oncol"},{"issue":"4","key":"1892_CR135","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1158\/1078-0432.CCR-06-2309","volume":"13","author":"JJ Vredenburgh","year":"2007","unstructured":"Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253\u20131259. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2309","journal-title":"Clin Cancer Res"},{"issue":"30","key":"1892_CR136","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","volume":"25","author":"JJ Vredenburgh","year":"2007","unstructured":"Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722\u20134729. https:\/\/doi.org\/10.1200\/JCO.2007.12.2440","journal-title":"J Clin Oncol"},{"issue":"28","key":"1892_CR137","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733\u20134740. https:\/\/doi.org\/10.1200\/JCO.2008.19.8721","journal-title":"J Clin Oncol"},{"issue":"9","key":"1892_CR138","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(14)70314-6","volume":"15","author":"W Taal","year":"2014","unstructured":"Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH et al (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15(9):943\u2013953. https:\/\/doi.org\/10.1016\/S1470-2045(14)70314-6","journal-title":"Lancet Oncol"},{"key":"1892_CR139","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1200\/JCO.2016.34.15_suppl.2001","volume":"34","author":"W Wick","year":"2016","unstructured":"Wick W, Brandes A, Gorlia T, Bendszus M, Sahm F, Taal W, Taphoorn MJ, Domont J et al (2016) EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma. J Clin Oncol 34:2001\u20132001. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.2001","journal-title":"J Clin Oncol"},{"issue":"8","key":"1892_CR140","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709\u2013722. https:\/\/doi.org\/10.1056\/NEJMoa1308345","journal-title":"N Engl J Med"},{"issue":"14","key":"1892_CR141","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.2015.63.4691","volume":"34","author":"U Herrlinger","year":"2016","unstructured":"Herrlinger U, Schafer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V et al (2016) Bevacizumab plus irinotecan versus temozolomide in newly diagnosed O6-methylguanine-DNA methyltransferase nonmethylated glioblastoma: the randomized GLARIUS trial. J Clin Oncol 34(14):1611\u20131619. https:\/\/doi.org\/10.1200\/JCO.2015.63.4691","journal-title":"J Clin Oncol"},{"issue":"1","key":"1892_CR142","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ccr.2006.11.020","volume":"11","author":"C Calabrese","year":"2007","unstructured":"Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW et al (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11(1):69\u201382. https:\/\/doi.org\/10.1016\/j.ccr.2006.11.020","journal-title":"Cancer Cell"},{"issue":"3","key":"1892_CR143","doi-asserted-by":"publisher","first-page":"122","DOI":"10.18632\/oncotarget.234","volume":"2","author":"RS Samant","year":"2011","unstructured":"Samant RS, Shevde LA (2011) Recent advances in anti-angiogenic therapy of cancer. Oncotarget 2(3):122\u2013134. https:\/\/doi.org\/10.18632\/oncotarget.234","journal-title":"Oncotarget"},{"key":"1892_CR144","doi-asserted-by":"publisher","first-page":"d7684","DOI":"10.1136\/bmj.d7684","volume":"343","author":"JH Tanne","year":"2011","unstructured":"Tanne JH (2011) FDA cancels approval for bevacizumab in advanced breast cancer. BMJ 343:d7684. https:\/\/doi.org\/10.1136\/bmj.d7684","journal-title":"BMJ"},{"issue":"17","key":"1892_CR145","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1200\/JCO.2009.26.3988","volume":"28","author":"TT Batchelor","year":"2010","unstructured":"Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J et al (2010) Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28(17):2817\u20132823. https:\/\/doi.org\/10.1200\/JCO.2009.26.3988","journal-title":"J Clin Oncol"},{"key":"1892_CR146","doi-asserted-by":"publisher","first-page":"CD008218","DOI":"10.1002\/14651858.CD008218.pub4","volume":"11","author":"M Ameratunga","year":"2018","unstructured":"Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J, Khasraw M (2018) Anti-angiogenic therapy for high-grade glioma. Cochrane Database Syst Rev 11:CD008218. https:\/\/doi.org\/10.1002\/14651858.CD008218.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"1892_CR147","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1159\/000467379","volume":"31","author":"J Jo","year":"2018","unstructured":"Jo J, Wen PY (2018) Antiangiogenic therapy of high-grade gliomas. Prog Neurol Surg 31:180\u2013199. https:\/\/doi.org\/10.1159\/000467379","journal-title":"Prog Neurol Surg"},{"issue":"12","key":"1892_CR148","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/S1474-4422(08)70260-6","volume":"7","author":"AD Norden","year":"2008","unstructured":"Norden AD, Drappatz J, Wen PY (2008) Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 7(12):1152\u20131160. https:\/\/doi.org\/10.1016\/S1474-4422(08)70260-6","journal-title":"Lancet Neurol"},{"issue":"6","key":"1892_CR149","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1097\/CCO.0b013e32831186ba","volume":"20","author":"AD Norden","year":"2008","unstructured":"Norden AD, Drappatz J, Wen PY (2008) Antiangiogenic therapy in malignant gliomas. Curr Opin Oncol 20(6):652\u2013661. https:\/\/doi.org\/10.1097\/CCO.0b013e32831186ba","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"1892_CR150","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/neuonc\/nop027","volume":"12","author":"JF de Groot","year":"2010","unstructured":"de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA (2010) Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-Oncology 12(3):233\u2013242. https:\/\/doi.org\/10.1093\/neuonc\/nop027","journal-title":"Neuro-Oncology"},{"issue":"1","key":"1892_CR151","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3171\/2008.4.17492","volume":"110","author":"A Narayana","year":"2009","unstructured":"Narayana A, Kelly P, Golfinos J, Parker E, Johnson G, Knopp E, Zagzag D, Fischer I et al (2009) Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 110(1):173\u2013180. https:\/\/doi.org\/10.3171\/2008.4.17492","journal-title":"J Neurosurg"},{"issue":"29","key":"1892_CR152","doi-asserted-by":"publisher","first-page":"10185","DOI":"10.1073\/pnas.0803194105","volume":"105","author":"F Kuhnert","year":"2008","unstructured":"Kuhnert F, Tam BY, Sennino B, Gray JT, Yuan J, Jocson A, Nayak NR, Mulligan RC et al (2008) Soluble receptor-mediated selective inhibition of VEGFR and PDGFRbeta signaling during physiologic and tumor angiogenesis. Proc Natl Acad Sci U S A 105(29):10185\u201310190. https:\/\/doi.org\/10.1073\/pnas.0803194105","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"1892_CR153","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1200\/JCO.2014.55.9575","volume":"33","author":"C Lu-Emerson","year":"2015","unstructured":"Lu-Emerson C, Duda DG, Emblem KE, Taylor JW, Gerstner ER, Loeffler JS, Batchelor TT, Jain RK (2015) Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol 33(10):1197\u20131213. https:\/\/doi.org\/10.1200\/JCO.2014.55.9575","journal-title":"J Clin Oncol"},{"issue":"3","key":"1892_CR154","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/neuonc\/not226","volume":"16","author":"E Tabouret","year":"2014","unstructured":"Tabouret E, Boudouresque F, Barrie M, Matta M, Boucard C, Loundou A, Carpentier A, Sanson M et al (2014) Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro-Oncology 16(3):392\u2013399. https:\/\/doi.org\/10.1093\/neuonc\/not226","journal-title":"Neuro-Oncology"},{"issue":"18","key":"1892_CR155","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1212\/WNL.0000000000001543","volume":"84","author":"QG D'Alessandris","year":"2015","unstructured":"D'Alessandris QG, Martini M, Cenci T, Capo G, Ricci-Vitiani L, Larocca LM, Pallini R (2015) VEGF isoforms as outcome biomarker for anti-angiogenic therapy in recurrent glioblastoma. Neurology 84(18):1906\u20131908. https:\/\/doi.org\/10.1212\/WNL.0000000000001543","journal-title":"Neurology"},{"issue":"9","key":"1892_CR156","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1002\/cncr.29234","volume":"121","author":"J Zhong","year":"2015","unstructured":"Zhong J, Ali AN, Voloschin AD, Liu Y, Curran WJ Jr, Crocker IR, Shu HK (2015) Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab. Cancer 121(9):1456\u20131462. https:\/\/doi.org\/10.1002\/cncr.29234","journal-title":"Cancer"},{"issue":"1","key":"1892_CR157","doi-asserted-by":"publisher","first-page":"8748","DOI":"10.1038\/s41598-018-27116-7","volume":"8","author":"L Guarnaccia","year":"2018","unstructured":"Guarnaccia L, Navone SE, Trombetta E, Cordiglieri C, Cherubini A, Crisa FM, Rampini P, Miozzo M et al (2018) Angiogenesis in human brain tumors: screening of drug response through a patient-specific cell platform for personalized therapy. Sci Rep 8(1):8748. https:\/\/doi.org\/10.1038\/s41598-018-27116-7","journal-title":"Sci Rep"},{"issue":"8","key":"1892_CR158","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrc2442","volume":"8","author":"G Bergers","year":"2008","unstructured":"Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8(8):592\u2013603. https:\/\/doi.org\/10.1038\/nrc2442","journal-title":"Nat Rev Cancer"},{"issue":"17","key":"1892_CR159","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.1073\/pnas.172398299","volume":"99","author":"J Holash","year":"2002","unstructured":"Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R et al (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99(17):11393\u201311398. https:\/\/doi.org\/10.1073\/pnas.172398299","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1892_CR160","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11060-008-9745-8","volume":"92","author":"AD Norden","year":"2009","unstructured":"Norden AD, Drappatz J, Muzikansky A, David K, Gerard M, McNamara MB, Phan P, Ross A et al (2009) An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neuro-Oncol 92(2):149\u2013155. https:\/\/doi.org\/10.1007\/s11060-008-9745-8","journal-title":"J Neuro-Oncol"},{"issue":"3","key":"1892_CR161","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1215\/15228517-2008-001","volume":"10","author":"R Du","year":"2008","unstructured":"Du R, Petritsch C, Lu K, Liu P, Haller A, Ganss R, Song H, Vandenberg S et al (2008) Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM. Neuro-Oncology 10(3):254\u2013264. https:\/\/doi.org\/10.1215\/15228517-2008-001","journal-title":"Neuro-Oncology"},{"issue":"3","key":"1892_CR162","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3892\/ol.2017.5567","volume":"13","author":"Q Xue","year":"2017","unstructured":"Xue Q, Cao L, Chen XY, Zhao J, Gao L, Li SZ, Fei Z (2017) High expression of MMP9 in glioma affects cell proliferation and is associated with patient survival rates. Oncol Lett 13(3):1325\u20131330. https:\/\/doi.org\/10.3892\/ol.2017.5567","journal-title":"Oncol Lett"},{"issue":"1","key":"1892_CR163","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","volume":"11","author":"TT Batchelor","year":"2007","unstructured":"Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP et al (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11(1):83\u201395. https:\/\/doi.org\/10.1016\/j.ccr.2006.11.021","journal-title":"Cancer Cell"},{"issue":"2","key":"1892_CR164","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s11060-010-0324-4","volume":"102","author":"G Minniti","year":"2011","unstructured":"Minniti G, Salvati M, Arcella A, Buttarelli F, D'Elia A, Lanzetta G, Esposito V, Scarpino S et al (2011) Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neuro-Oncol 102(2):311\u2013316. https:\/\/doi.org\/10.1007\/s11060-010-0324-4","journal-title":"J Neuro-Oncol"},{"issue":"16","key":"1892_CR165","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1200\/JCO.2009.26.6650","volume":"28","author":"R Stupp","year":"2010","unstructured":"Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF et al (2010) Phase I\/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28(16):2712\u20132718. https:\/\/doi.org\/10.1200\/JCO.2009.26.6650","journal-title":"J Clin Oncol"},{"issue":"8","key":"1892_CR166","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.neo.2015.08.002","volume":"17","author":"P Minder","year":"2015","unstructured":"Minder P, Zajac E, Quigley JP, Deryugina EI (2015) EGFR regulates the development and microarchitecture of intratumoral angiogenic vasculature capable of sustaining cancer cell intravasation. Neoplasia 17(8):634\u2013649. https:\/\/doi.org\/10.1016\/j.neo.2015.08.002","journal-title":"Neoplasia"},{"issue":"2","key":"1892_CR167","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/jcp.21706","volume":"219","author":"G Ferrari","year":"2009","unstructured":"Ferrari G, Cook BD, Terushkin V, Pintucci G, Mignatti P (2009) Transforming growth factor-beta 1 (TGF-beta1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis. J Cell Physiol 219(2):449\u2013458. https:\/\/doi.org\/10.1002\/jcp.21706","journal-title":"J Cell Physiol"},{"issue":"26","key":"1892_CR168","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1200\/JCO.2012.47.2464","volume":"31","author":"TT Batchelor","year":"2013","unstructured":"Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T et al (2013) Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31(26):3212\u20133218. https:\/\/doi.org\/10.1200\/JCO.2012.47.2464","journal-title":"J Clin Oncol"},{"issue":"7","key":"1892_CR169","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1200\/JCO.2009.23.2595","volume":"28","author":"W Wick","year":"2010","unstructured":"Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M et al (2010) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28(7):1168\u20131174. https:\/\/doi.org\/10.1200\/JCO.2009.23.2595","journal-title":"J Clin Oncol"},{"issue":"19","key":"1892_CR170","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1200\/JCO.2010.34.1636","volume":"29","author":"JF de Groot","year":"2011","unstructured":"de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF et al (2011) Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 29(19):2689\u20132695. https:\/\/doi.org\/10.1200\/JCO.2010.34.1636","journal-title":"J Clin Oncol"},{"issue":"2","key":"1892_CR171","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11060-012-1009-y","volume":"111","author":"A Muhic","year":"2013","unstructured":"Muhic A, Poulsen HS, Sorensen M, Grunnet K, Lassen U (2013) Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme. J Neuro-Oncol 111(2):205\u2013212. https:\/\/doi.org\/10.1007\/s11060-012-1009-y","journal-title":"J Neuro-Oncol"},{"issue":"8","key":"1892_CR172","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/neuonc\/noq025","volume":"12","author":"FM Iwamoto","year":"2010","unstructured":"Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA, Deangelis LM, Abrey LE et al (2010) Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro-Oncology 12(8):855\u2013861. https:\/\/doi.org\/10.1093\/neuonc\/noq025","journal-title":"Neuro-Oncology"},{"issue":"4","key":"1892_CR173","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1158\/1078-0432.CCR-12-1707","volume":"19","author":"DA Reardon","year":"2013","unstructured":"Reardon DA, Groves MD, Wen PY, Nabors L, Mikkelsen T, Rosenfeld S, Raizer J, Barriuso J et al (2013) A phase I\/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin Cancer Res 19(4):900\u2013908. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1707","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1892_CR174","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11060-010-0217-6","volume":"101","author":"DA Reardon","year":"2011","unstructured":"Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, Marcello J, Herndon JE 2nd et al (2011) Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: Results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neuro-Oncol 101(1):57\u201366. https:\/\/doi.org\/10.1007\/s11060-010-0217-6","journal-title":"J Neuro-Oncol"},{"issue":"1","key":"1892_CR175","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11060-012-0988-z","volume":"111","author":"TN Kreisl","year":"2013","unstructured":"Kreisl TN, Smith P, Sul J, Salgado C, Iwamoto FM, Shih JH, Fine HA (2013) Continuous daily sunitinib for recurrent glioblastoma. J Neuro-Oncol 111(1):41\u201348. https:\/\/doi.org\/10.1007\/s11060-012-0988-z","journal-title":"J Neuro-Oncol"},{"issue":"12","key":"1892_CR176","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1093\/neuonc\/nos265","volume":"14","author":"TN Kreisl","year":"2012","unstructured":"Kreisl TN, McNeill KA, Sul J, Iwamoto FM, Shih J, Fine HA (2012) A phase I\/II trial of vandetanib for patients with recurrent malignant glioma. Neuro-Oncology 14(12):1519\u20131526. https:\/\/doi.org\/10.1093\/neuonc\/nos265","journal-title":"Neuro-Oncology"},{"issue":"8","key":"1892_CR177","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699\u2013708. https:\/\/doi.org\/10.1056\/NEJMoa1308573","journal-title":"N Engl J Med"},{"issue":"5","key":"1892_CR178","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/neuonc\/nou356","volume":"17","author":"LB Nabors","year":"2015","unstructured":"Nabors LB, Fink KL, Mikkelsen T, Grujicic D, Tarnawski R, Nam DH, Mazurkiewicz M, Salacz M et al (2015) Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro-Oncology 17(5):708\u2013717. https:\/\/doi.org\/10.1093\/neuonc\/nou356","journal-title":"Neuro-Oncology"},{"issue":"10","key":"1892_CR179","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","volume":"15","author":"R Stupp","year":"2014","unstructured":"Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B et al (2014) Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 15(10):1100\u20131108. https:\/\/doi.org\/10.1016\/S1470-2045(14)70379-1","journal-title":"Lancet Oncol"},{"issue":"8","key":"1892_CR180","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1212\/01.wnl.0000208958.29600.87","volume":"66","author":"WB Pope","year":"2006","unstructured":"Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF (2006) MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66(8):1258\u20131260. https:\/\/doi.org\/10.1212\/01.wnl.0000208958.29600.87","journal-title":"Neurology"},{"issue":"10","key":"1892_CR181","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1002\/cncr.24213","volume":"115","author":"DA Reardon","year":"2009","unstructured":"Reardon DA, Egorin MJ, Desjardins A, Vredenburgh JJ, Beumer JH, Lagattuta TF, Gururangan S, Herndon JE 2nd et al (2009) Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer 115(10):2188\u20132198. https:\/\/doi.org\/10.1002\/cncr.24213","journal-title":"Cancer"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-020-01892-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12035-020-01892-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-020-01892-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T01:19:55Z","timestamp":1615252795000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-020-01892-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,9]]},"references-count":181,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["1892"],"URL":"https:\/\/doi.org\/10.1007\/s12035-020-01892-8","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,9]]},"assertion":[{"value":"1 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}